Holocene Advisors
FATE icon

Holocene Advisors’s Fate Therapeutics FATE Stock Holding History

Holocene Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,527,747
Closed -$18.6M – 750
2024
Q1 		$18.6M Buy
+2,527,747
New +$15.6M 0.07% 219
2021
Q4 		– Sell
-238,576
Closed -$14.1M – 898
2021
Q3 		$14.1M Sell
238,576
-1,615
-0.7% -$127K 0.08% 220
2021
Q2 		$20.8M Buy
+240,191
New +$19.4M 0.12% 190

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Holocene Advisors's FATE Position: Q2 2024 in Review

Holocene Advisors sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 2,527,747 shares — an estimated $18.6M sold.

Holocene Advisors first reported a position in FATE in Q2 2021 and held it in 3 quarters. The position peaked at $20.8M in Q2 2021. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Holocene Advisors reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Holocene Advisors sold 2,527,747 Fate Therapeutics shares in Q2 2024, an estimated $18.6M.
  • Holocene Advisors first reported a position in Fate Therapeutics in Q2 2021 and held it in 3 quarters.
  • Holocene Advisors's Fate Therapeutics position peaked at $20.8M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Holocene Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.